<DOC>
	<DOC>NCT01240642</DOC>
	<brief_summary>The purpose of this study is to determine the effect of the ASA404 infusion rate and co-administrating ASA404 with paclitaxel + carbopaltin chemotherapy regimen or docetaxel on the pharamcokinetics (PK) of free and total ASA404.</brief_summary>
	<brief_title>An Open-label, Dose Escalation Multi-center Study in Patients With Advanced Cancer to Determine the Infusion Rate Effect of ASA 404 With Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokietics of Free and Total ASA404</brief_title>
	<detailed_description />
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms, Second Primary</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Vadimezan</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients having histologicallyproven solid tumors, who are either refractory to standard chemotherapy Patients whom chemotherapy with an investigaional agent in combination with docetaxel, or paclitaxel + carboplatin is appropriate Creatinine clearance according to CockcroftGault formula : Normal &gt; 80 mL/min, Mild 5080 mL/min, Moderate 30&lt;50 mL/min A minimum of 4 weeks must have elapsed since the last treatment with other cancer therapies Potassium, calcium, magnesium and phosphorus values within the normal range Body Mass Index (BMI) must be within the range of 18 and 30 Patients having CNS metastases, must have a CT or MRI of the brain performed to rule out CNS metastases Patients with leptomeningeal disease metastases Radiotherapy &lt;/ weeks prior to starting study drug Major surgery &lt;/ 4 weeks prior to the start of study Administration of CYP1A2 and CYP3A4/5 enzyme inducing or inhibiting drugs within 14 days prior to starting study drug Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Advanced or metastatic cancer</keyword>
	<keyword>refractory</keyword>
	<keyword>core phase</keyword>
	<keyword>extension phase</keyword>
	<keyword>dose escalation</keyword>
	<keyword>standard chemotherapy</keyword>
	<keyword>doctaxel</keyword>
	<keyword>paclitaxel</keyword>
	<keyword>carboplatin</keyword>
	<keyword>safety</keyword>
	<keyword>tolerability</keyword>
</DOC>